VIVUS, Inc. (VVUS) Ticks Higher as Arena (ARNA) Pulls BELVIQ MAA in Europe
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is indicated higher in early trading Friday following word that a key competitor will be less fierce in at least one market.
After markets closed on Thursday, Arena Pharmaceuticals (Nasdaq: ARNA) notified the European Medicines Agency that the company is withdrawing the BELVIQ Marketing Authorization Application (MAA) in the European Union. Arena is currently evaluating the best approach for submitting at a later date.
Another name to watch is Orexigen (Nasdaq: OREX), which is working on its own weight-loss pill in Contrave.
After markets closed on Thursday, Arena Pharmaceuticals (Nasdaq: ARNA) notified the European Medicines Agency that the company is withdrawing the BELVIQ Marketing Authorization Application (MAA) in the European Union. Arena is currently evaluating the best approach for submitting at a later date.
Another name to watch is Orexigen (Nasdaq: OREX), which is working on its own weight-loss pill in Contrave.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
- HOOKIPA Pharma Inc. (HOOK) Receives FDA Clearance of INDA for HB-700
- Regeneron (REGN) and Mammoth Biosciences Collaborate over Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
